# Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell

> **NCT03180281** · NA · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 135 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** DPP4
- **DRUG:** Insulin
- **DRUG:** SU

## Key facts

- **NCT ID:** NCT03180281
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-01
- **Primary completion:** 2020-01-01
- **Final completion:** 2020-01-01
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2017-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03180281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03180281, "Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03180281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*